|
|
|
|
||
Re: bispecifics etc.Another immunotherapy platform I'm looking into is the Cloudbreak by Cidara Therapeutics (CDTX)... They are not currently pursuing trials into immuno-oncology, but they are targeting improved immune response across a variety of other disease indications, and the technology looks to be target-adaptive. The stock is currently trading about 20% above 52-week lows, and also looks to be heading back toward the 200MA. There may be unrealized value in Cloudbreak... |
return to message board, top of board |